GlassScriptPhysician profile
Ruby M Marie-Northrup
NPI 1063570620
$2,204.19
in general payments reported to CMS, 2019-2025
26 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $222 · 2021: $325 · 2022: $248 · 2023: $546 · 2024: $550 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.79 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $522.26 | 2021-2024 | |
| Astellas Pharma US INC | $237.05 | 2023-2024 | Veozah |
| Pfizer INC. | $181.77 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $80.96 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.62 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $54.99 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $33.13 | 2019-2025 | Evenity |
| Lilly USA, LLC | $32.76 | 2022-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $30.02 | 2025 | Airsupra, Farxiga |
| Abbott Laboratories | $29.70 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $25.14 | 2022 | |
| Axsome Therapeutics, INC. | $20.50 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $20.10 | 2023 | Rexulti |
| Amarin Pharma, INC. | $19.74 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.16 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Ardelyx, INC. | $15.59 | 2024 | Ibsrela |
| Lundbeck LLC | $15.42 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $15.19 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.97 | 2022 | |
| Boston Scientific Corporation | $13.44 | 2021 | |
| Esperion Therapeutics, INC. | $12.99 | 2021 | |
| Allergan, INC. | $10.99 | 2020 | |
| Medtronic USA, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Marie-Northrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.